Legal Risks of Long-Term Peptide Use in Bodybuilding

Why long-term use changes the legal picture

Most legal write-ups about peptides picture a single order. Lifters who use peptides for years leave a longer trail: dozens of orders, a string of sellers as old ones close, packages that cross borders, and sometimes a move from untested training into tested competition. Each step meets a different body of law.

This page covers those rules as they stood in October 2026, mostly from a US point of view, with notes on sport and Australia. It summarizes regulatory documents and news reports. It isn't legal advice, and state laws, which we didn't review, can add their own restrictions. For the health side of multi-year use, see our overview of long-term peptide effects in bodybuilding.

What the research-use-only label does

Nearly every peptide sold online to lifters carries a "research use only, not for human consumption" label. The label exists for the seller's benefit. US drug law turns on intended use, and FDA's 2026 warning letters show how little the label counts once a website points toward human use.

On March 31, 2026, FDA told Gram Peptides that its retatrutide and tirzepatide were unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act, despite the research-only statements on its labels. The agency also classed the bacteriostatic water sold alongside the peptides as a drug, because selling the two together showed the water was meant for injection. A batch of letters dated August 24, 2026 went further. The letter to Peak Performance Peptides quoted product copy written in careful research language, such as "studied for effects on glycemic control," as evidence that the products were meant for people.

Criminal cases are rare, but they happen. On July 30, 2026, a federal judge in Indiana sentenced Matthew Kawa, owner of Paradigm Peptides, to 70 months in prison, according to CBS News. Kawa had pleaded guilty to selling unapproved drugs and importing them illegally. In his plea he admitted he knew the products were sold for human consumption, and he admitted that the company forged lab certificates.

Every one of these actions targeted a seller. In the 2026 letters and cases we reviewed, nobody was charged for owning a non-controlled peptide for personal use. For a long-term user, the effect shows up in supply instead. Sellers shut down or rebrand, and copycat sites fill the gap; CBS News found one using Paradigm's name and what appeared to be the same label design. Each switch means trusting a source with no track record.

Controlled substances and the adulteration problem

The Drug Enforcement Administration (DEA) enforces the Controlled Substances Act. As of October 2026, none of the peptides lifters usually discuss, including BPC-157, TB-500, CJC-1295, ipamorelin, sermorelin and MOTS-c, appears on DEA's alphabetical list of controlled substances. Anabolic steroids and testosterone are Schedule III. That is the main reason federal law treats owning a peptide differently from owning a steroid. Our long-term comparison of peptides and anabolic steroids covers the health side of that contrast.

What's actually in the vial complicates this. In the Paradigm case, prosecutors said government tests of six of the company's SARM products found real testosterone in all six. A buyer can end up holding a scheduled drug without knowing it. Someone who orders from many sources over several years has more chances of receiving a mislabeled product, and short of independent lab testing there's no practical way to rule it out.

Compounding and prescriptions, as of October 2026

A prescription filled by a licensed compounding pharmacy is the main lawful route to peptides in the US. It covers far fewer compounds than the gray market sells.

On April 15, 2026, FDA gave notice that it would remove 12 peptides, among them BPC-157, TB-500 and MOTS-c, from Category 2 of its 503A bulk substances list, the group flagged for significant safety risks. The nominations had been withdrawn, and the removal took effect about a week later. It isn't permission to compound. The 12 now sit in no category, and the law firm Orrick advised pharmacies not to compound any of them on the strength of the removal alone.

In July 2026, FDA's Pharmacy Compounding Advisory Committee recommended adding six of those peptides to the list, BPC-157, TB-500 and MOTS-c among them. A recommendation isn't a rule. As of October 2026, FDA hasn't proposed one, so none of the six can be lawfully compounded from bulk yet. CJC-1295 and ipamorelin had already been voted down by the committee in 2024.

Sermorelin is the exception lifters mention most. It was once FDA-approved as Geref, and in 2013 FDA determined that Geref wasn't withdrawn from sale for safety or effectiveness reasons. That history is why US pharmacies can still compound sermorelin on prescription, although the adult evidence behind its popularity with lifters is thin.

Importing, order after order

Long-term users who buy from overseas face customs with every package. Officers at the Port of Cincinnati seized about 5,000 individual peptide shipments from a shipper in China between December 2025 and late March 2026, hidden inside mis-manifested master cartons. The seized products included GLP-1 drugs as well as MOTS-c and Semax. U.S. Customs and Border Protection's release describes the seizures; it doesn't mention charges against the people the packages were addressed to.

FDA's personal importation guidance says products that violate FDA law are "generally not permitted." Officers may allow personal-use imports in limited cases, generally up to a three-month supply, when the buyer affirms personal use in writing and names a US-licensed doctor responsible for treatment (or shows the treatment began abroad). A research-labeled vial bought without a prescription rarely fits. Each shipment is judged on its own, so over years of buying, the odds that some packages never arrive keep adding up.

Australia is more explicit. In an April 13, 2026 safety alert, the Therapeutic Goods Administration (TGA) said research-use-only disclaimers don't make supply lawful and don't permit importation. Under its Personal Importation Scheme, unclearly labeled vials "will not be considered for release," and a prescription is needed where the medicine requires one. The alert named BPC-157, TB-500, CJC-1295, GHK-Cu and retatrutide as examples of unapproved peptide products.

Tested sport: why past use carries forward

For athletes in tested sport, anti-doping rules matter more than criminal law. As of October 2026, WADA's 2026 Prohibited List bans all of the following at all times, in and out of competition:

Many older guides file TB-500 under S0, but the list names it in S2.3. The 2027 list takes effect on January 1, 2027. According to USADA's athlete advisory, it adds peptides in general to the S0 examples, and USADA warns that a peptide doesn't have to be named to be prohibited.

Athletes are strictly liable for whatever is in their sample. Under the 2021 World Anti-Doping Code, an intentional violation brings a four-year ban; otherwise the standard ban is two years. S0 substances are Specified Substances, which means the anti-doping organization has to prove intent before the four-year ban applies.

Time matters here. The Code lets anti-doping organizations store a negative sample and re-analyze it later, and a case can be brought up to ten years after the violation. For someone with a long tested career, a clean result on the day isn't necessarily the end of it.

Where the law could change next

Several decisions were still open in October 2026:

• FDA hasn't said whether it will follow the July 2026 committee votes. A second committee meeting, covering GHK-Cu among others, is planned before the end of February 2027.
• The 2026 warning letters went to sellers. We found no sign that enforcement is shifting toward individual buyers, though agencies rarely announce that kind of change in advance.
• How anti-doping bodies apply the broader 2027 S0 wording to new peptides will only become clear case by case.

Several compounds on this page have moved between FDA categories since 2023, so a multi-year plan built on today's rules needs rechecking along the way. The physiological case for planned breaks is a separate question, covered in our article on long-term peptide cycling strategies.